Immunoprecise Stock Price, News & Analysis

ImmunoPrecise Antibodies (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has announced its participation in The Microcap Conference 2025. The event will be held from January 28-30, 2025, in Atlantic City, NJ. During the conference, IPA's management team will deliver a corporate presentation and conduct one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.

ImmunoPrecise Antibodies (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, has announced its participation in The Microcap Conference 2025. The event will be held from January 28-30, 2025, in Atlantic City, NJ. During the conference, IPA's management team will deliver a corporate presentation and conduct one-on-one meetings with institutional and individual investors to showcase the company's recent developments, growth strategy, and investment opportunities.

ImmunoPrecise Antibodies (IPA) reported Q2 FY25 financial results with revenue of $6.1 million, flat compared to Q2 FY24. The company reported a net loss of $2.6 million, or $(0.09) per share. Project revenue was $5.4 million, while product sales and cryostorage revenue reached $0.7 million.

Key developments include the planned relocation of corporate headquarters to Austin, Texas, and showcase of the LENSai Platform at major industry events. The company entered partnerships with BioNTech and Mayo Clinic, progressed its TATX-112 program for ADC therapies, and advanced two novel antibodies to clinical-stage programs. Cash position stood at $3.6 million as of October 31, 2024.

ImmunoPrecise Antibodies (IPA), an AI-driven biotherapeutic research and technology company, has announced its participation in The Benchmark Company's 13th Annual Discovery One-on-One Investor Conference. The event will take place on December 11th, 2024, at the New York Athletic Club in New York City.

Dr. Jennifer Bath, President and CEO, will represent IPA at the conference, conducting one-on-one meetings with investors and analysts. The conference provides a unique platform for emerging growth and dynamic publicly traded companies to connect directly with institutional and individual investors.

Interested parties must register for the conference to schedule meetings with Dr. Bath through the conference platform.

IPA (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, will report its financial results and recent business highlights for the second quarter of fiscal year 2025 on December 10, 2024. The company will host a live conference call and webcast at 10:30 AM ET on the same day to discuss the results and provide a corporate update. The call will include a question-and-answer period with ImmunoPrecise management. Participants can join via provided dial-in numbers or access the webcast through a link on the company's IR page. For more details, visit the company's profile on www.sedarplus.com and www.sec.gov.

ImmunoPrecise Antibodies (NASDAQ: IPA) has announced a breakthrough in cancer research through its TATX-112 program, developing specialized antibodies targeting TrkB protein in aggressive cancers. The company is advancing two programs: TATX-200 for T cell engagers and TATX-112 for antibody-drug conjugates (ADCs). Recent tests showed promising results with antibodies capable of infiltrating and eliminating TrkB-expressing cells in vitro. This development positions IPA in the growing ADC market, projected to reach $20.7 billion by 2028.

ImmunoPrecise Antibodies (NASDAQ: IPA) announces its upcoming TECHDAY event on November 15, 2024, in Cambridge, Massachusetts. The event will showcase the company's latest advancements in AI-driven drug discovery and biologics innovation. Key presentations include Dr. Van Hyfte's demonstration of the LENSai platform, featuring HYFT® Universal Fingerprints for multi-omics integration, and Dr. Sato's presentation on IPA's B Cell Discovery Platform with AI and NGS workflows. The event includes a fireside chat on drug discovery through data integration and AI-powered insights, featuring collaboration with InterSystems IRIS data platform.

ImmunoPrecise Antibodies (IPA) announces its contribution to a groundbreaking Mayo Clinic study on age-related mitochondrial dysfunction, published in the journal Autophagy. Using its proprietary rabbit B Cell Select™ platform, IPA developed specific antibodies targeting phosphorylated ubiquitin, a marker of mitochondrial damage common in aging and neurodegenerative diseases. The research advances understanding of conditions like Parkinson's and Alzheimer's. IPA is positioned to tap into the anti-aging market, projected to reach $81.01 billion by 2028 with an 8.2% CAGR. Through its subsidiary Talem Therapeutics, IPA maintains a pipeline focusing on therapeutic antibodies while supporting external research.

ImmunoPrecise Antibodies (IPA) and Biotheus have entered into a Material Transfer and Evaluation Agreement (MTEA) for the development of a bispecific therapy against solid tumors. Biotheus will evaluate Talem Therapeutics' AI-enhanced TATX-20 lead candidate for potential use in creating novel bispecific antibodies to treat hypoxic solid tumors.

The collaboration aims to combine IPA's AI-driven antibody discovery expertise with Biotheus' bispecific engineering capabilities. If successful, Biotheus plans to further develop the bispecific molecules, targeting the creation of a clinically successful product for treating hypoxic solid tumors resistant to current therapies.

This strategic partnership could accelerate the development of innovative cancer treatments and potentially lead to breakthrough clinical outcomes, bringing value to both companies and patients in need of advanced treatment options.